home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 11/12/25

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch

2025-11-12 08:59:00 ET More on Immix Biopharma Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. ...
IMMX - Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch and commercial buildout for...

IMMX - Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

2025-11-06 14:39:40 ET Topline Summary Read the full article on Seeking Alpha For further details see: Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

IMMX - Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amylo...
IMMX - Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host in...

IMMX - Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 a...

IMMX - Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious...
IMMX - Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We...

IMMX - Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clini...

IMMX - Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious d...
Previous 10 Next 10